Effects of phosphodiesterase inhibitors on interleukin-4 and interleukin-13 generation from human basophils
Open Access
- 1 August 2004
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 142 (8) , 1265-1272
- https://doi.org/10.1038/sj.bjp.0705892
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Evidence that the anti‐spasmogenic effect of the β‐adrenoceptor agonist, isoprenaline, on guinea‐pig trachealis is not mediated by cyclic AMP‐dependent protein kinaseBritish Journal of Pharmacology, 2001
- Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?Trends in Pharmacological Sciences, 1997
- Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future?Trends in Pharmacological Sciences, 1997
- Purified human peripheral blood basophils release interleukin‐13 and preformed interleukin‐4 following immunological activationEuropean Journal of Immunology, 1996
- The role of the basophil in allergic inflammationAllergy, 1995
- Pulmonary immune cells in health and disease: mast cells and basophilsEuropean Respiratory Journal, 1994
- Human peripheral blood basophils primed by interleukin 3 (IL-3) produce IL-4 in response to immunoglobulin E receptor stimulation.The Journal of Experimental Medicine, 1993
- Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitorsTrends in Pharmacological Sciences, 1990
- Modulation of Inflammation and Immunity by Cyclic AMPScience, 1974
- Histamine Release in vitro: Inhibition by Catecholamines and MethylxanthinesScience, 1968